OUR NEWS & EVENTS

REYKJAVIK, ICELAND – 15 June 2022 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), the clinical-stage biopharmaceutical company...

· First non-antibiotic macrolide to go into clinical development – targeting COPD · Safety, tolerability and pharmacokinetic...

REYKJAVIK, ICELAND – 9 May 2022 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), the clinical-stage biopharmaceutical company...

Grows team across Sweden, Denmark, Iceland, and the UK REYKJAVIK, ICELAND – 21 April 2022 – EpiEndo Pharmaceuticals (‘EpiEndo’), the...

REYKJAVIK, ICELAND – 24 March 2022 – EpiEndo Pharmaceuticals is pleased to announce the appointment of Stefan Petursson as Chief...

In the January edition of the Nordic Life Science Magazine (www.nordiclifescience.org), the leading life science business magazine in the...

EpiEndo Pharmaceuticals is an Icelandic clinical stage pharmaceutical company with a unique focus on impairment of epithelial barriers as...

EpiEndo Pharmaceuticals is a clinical stage pharmaceutical company with a unique focus on impairment of epithelial barriers as a common...

EpiEndo is a clinical stage pharmaceutical company with a unique focus on impairment of epithelial barriers as a common mechanism of many...

EpiEndo Pharma receives the Swedish American Life Sciences Summit (SALSS) Rising Star Award 2021 for its innovation and potential impact in

EpiEndo Pharmaceuticals Secures €20M Series A Funding to Advance Clinical Development of its Lead Compound EP395 for the Treatment of COPD

EpiEndo is announced as the winner of the Biotech & Pharmaceuticals category, at the European Innovation Council Investor Day on Health 2021

EpiEndo Pharma is the recipient of a €2.7 million convertible loan from the European Innovation Council (EIC) Fund.

First-in-Human Clinical Trial of EpiEndo’s Lead Compound, EP395, for Chronic Inflammatory Airway Diseases Commences at the Medicines...

EpiEndo Pharmaceuticals is pleased to announce the appointment of Dr. Sigríður Valgeirsdóttir and Robert Helgason to the Company’s Board

EpiEndo Pharmaceuticals is pleased to announce that their consortium project EPIcoliX has been officially recognized as a Eurostar...

EpiEndo Pharma Builds Science and Medical Leadership with Appointment of New CSO & CMO

REYKJAVIK, ICELAND – 24 February 2021 – EpiEndo Pharmaceuticals (www.epiendo.com) The Board of EpiEndo Pharmaceuticals is pleased to...

REYKJAVIK, ICELAND - 5 January 2021 - EpiEndo Pharmaceuticals (www.epiendo.com) announced today that the Company has received approval...

REYKJAVIK, ICELAND – 21 September 2020 – EpiEndo Pharmaceuticals (www.epiendo.com) is pleased to share important findings in a poster at...